bioAffinity Technologies will execute a 1-for-15 reverse stock split, effective at the open on Aug. 24, 2026.
Shares are expected to trade on a post-split basis on Nasdaq under BIAF. The move is intended to help the company comply with Nasdaq’s minimum bid-price rule.
The post-split common stock CUSIP will change to 09076W406.
Fractional shares will be cashed out.
The company expects about 592,373 shares outstanding immediately following the consolidation.
Options, incentive plan shares, and warrants will be adjusted proportionately; the publicly traded warrant CUSIP will remain unchanged.
BIAF•
